0000000000220285

AUTHOR

F. Verderame

showing 5 related works from this author

Ecografia con mezzo di contrasto versus TC multistrato nella valutazione dell’epatocarcinoma trattato mediante procedure non chirurgiche

2005

researchProduct

Heterogeneous delayed enhancement of hepatic parenchyma after intravenous infusion of sonographic contrast agent: a new hypothesis

2007

Purpose. The aim of this paper was to report a heterogeneous latephase hepatic enhancement pattern observed after administration of a sonographic contrast agent and to present an aetiological hypothesis for the phenomenon. Materials and methods. A total of 1,729 (1,012 women and 717 men; age range 28–82; mean age 51) patients underwent contrastenhanced sonography of the liver. The examination was performed with a low mechanical index (MI <0.09) after injection of sulphur-hexafluoride-filled microbubbles, using different fonographic equipment and different contrast-specific algorithms. Results. Heterogeneous delayed liver enhancement was observed in six patients in the late phase (180 s), wi…

AdultMalemedicine.medical_specialtyPathologyTime FactorsSulfur HexafluorideContrast MediaHepatic ArteryMesenteric VeinsmedicineHumansRadiology Nuclear Medicine and imagingSuperior mesenteric veinInfusions IntravenousUltrasound Microbubbles LiverPhospholipidsAgedUltrasonographyNeuroradiologyAged 80 and overMicrobubblesmedicine.diagnostic_testPortal Veinbusiness.industryUltrasoundEchogenicityInterventional radiologyGeneral MedicineMiddle AgedImage EnhancementPeripheralLiverMicrobubblesFemaleRadiologySettore MED/36 - Diagnostica Per Immagini E RadioterapiabusinessMechanical indexLiver CirculationLa radiologia medica
researchProduct

Pulse inversion e mezzo di contrasto sul rene di coniglio: effetti biologici

2005

researchProduct

ELF regimen in advanced gastrointestinal malignancies: An analysis of its clinical effectiveness and toxicity

2011

A multi-institutional phase 11 study of the combination of levofolinic acid 100 mg/m2, VP16 120 mg/m2 and 5-fluorouracil 500 mg/m2 for 3 consecutive days was carried out on a series of 73 evaluable patients with low performance status affected by locally advanced and/or metastatic gastrointestinal carcinomas. Site of primary tumor were: stomach 26, large bowel 20, pancreas 16, gall-bladder 5, and liver 6. Among patients with gastric carcinoma, 2 patients (8%) had a complete response with a mean duration of 6.8+ months, and 9 (35%) had a partial response with a mean duration of 5.8+ months, for an overall response rate of 43%. Overall response rate was largely unsatisfactory in colorectal ca…

Oncologymedicine.medical_specialtyCancer ResearchColorectal cancerGastroenterologyELF RegimenGall-bladder cancerPancreatic cancerInternal medicinemedicineELF regimenEtoposideLeukopeniaPerformance statusbusiness.industryStomachFolinic acidPancreatic cancermedicine.diseaseColorectal cancermedicine.anatomical_structureOncologyVomitingFluorouracilmedicine.symptombusinessLiver cancerGastric cancerLiver cancer
researchProduct

Vinorelbine and 5-fluorouracil bolus and/or continuous venous infusion plus levofolinic acid as second-line chemotherapy for metastatic breast cancer…

2006

Background: This retrospective study evaluated the activity and toxicity profile of a regimen of vinorelbine and 5-fluorouracil with levofolinic acid, given to a large series of patients with recurrent or refractory metastatic breast cancer after first-line chemotherapy. Patients and Methods: Overall, 286 evaluable patients were included in the analysis. Two chemotherapy schedules were reviewed: a) the bolus regimen consisted of levofolinic acid 100 mg/m(2) and 5-fluorouracil 375 mg/m(2) both administered i.v. on days 1,2 and 3, plus vinorelbine 25 mg/m(2) i.v. bolus on days I and 8 every 3 weeks; b) the infusional regimen of levofolinic acid 100 mg/m(2) given as a 2-hour infusion, followed…

FIRST-LINE CHEMOTHERAPYPHASE I-IINAVELBINEFOLINIC ACIDSALVAGE TREATMENTANTHRACYCLINECOLONY-STIMULATING FACTORCOMBINATIONFLUOROURACILLEUCOVORIN
researchProduct